NC
NCNA.US NuCana PLC
- Market cap
- USD 3.88M
- P/E
- -
- P/B
- 0.14x
- ROE
- -57.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NCNA.US undervalued?
Graham numberThe Graham number of NuCana PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NuCana PLC fundamental analysis
No fundamental analysis for NuCana PLC yet.
NuCana PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derive…
Full company profileNuCana PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NuCana PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 283K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 283K | 0.00 | 0.00 | - | - | - | - | - | -268K | -280K |
| Operating Income | -8.45M | -22.2M | -22.0M | -26.7M | -36.4M | -47.9M | -39.1M | -32.8M | -22.8M | -20.1M | -12.8M |
| EBITDA | 101K | 194K | 371K | 718K | -28.6M | -44.4M | -43.0M | -30.6M | -22.5M | -20.6M | -13.0M |
| Net Income | -6.05M | -23.1M | -13.8M | -21.4M | -30.7M | -40.5M | -32.0M | -27.6M | -19.0M | -29.4M | -11.4M |
| EPS | -951 | -3,687 | -2,165 | -3,312 | -4,050 | -3,894 | -3,065 | -2,628 | -1,280 | -13 | -2.48 |
| Balance Sheet | |||||||||||
| Total Assets | 27.2M | 96.4M | 87.2M | 70.3M | 108M | 77.5M | 58.3M | 27.8M | 14.8M | 29.8M | 24.6M |
| Total Liabilities | 1.97M | 2.94M | 5.59M | 6.75M | 8.56M | 11.9M | 19.8M | 12.9M | 8.82M | 5.51M | 4.89M |
| Shareholders' Equity | 25.2M | 93.4M | 81.6M | 63.5M | 99.2M | 65.5M | 38.5M | 14.9M | 5.95M | 24.3M | 19.7M |
| Cash & Short-term Investments | 20.0M | 86.7M | 77.0M | 52.0M | 87.4M | 60.3M | 41.9M | 17.2M | 6.75M | 24.3M | 18.5M |
| Total Debt | 0.00 | 0.00 | 0.00 | 806K | 645K | 371K | 639K | 396K | 190K | 676K | 668K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.26M | -8.71M | -12.2M | -23.8M | -21.6M | -23.8M | -23.2M | -26.4M | -19.1M | -7.47M | -8.81M |
| Capital Expenditure | 554K | 1.10M | 1.62M | 1.26M | 1.63M | 1.07M | 518K | 478K | 293K | 193K | 148K |
| Free Cash Flow | -9.82M | -9.80M | -13.8M | -25.1M | -23.3M | -24.9M | -23.7M | -26.9M | -19.4M | -7.66M | -8.92M |
| Ratios | |||||||||||
| ROE | -24.0% | -24.7% | -17.0% | -33.7% | -30.9% | -61.8% | -83.2% | -185.6% | -319.1% | -120.7% | -57.9% |
| ROA | -22.2% | -24.0% | -15.9% | -30.5% | -28.5% | -52.3% | -55.0% | -99.4% | -128.6% | -98.4% | -46.4% |
| Net Profit Margin | - | -8,157.2% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.03x | 0.03x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NuCana PLC dividends
NuCana PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:200 on Aug 11, 2025.
Who owns NuCana PLC
- Insiders 0.00%
- Institutions 1.94%
- Public & others 98.06%
- Shares outstanding 4.16M
- Free float 4.31M
Top funds holding NCNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| LUNIS Biotech Growth Opp Fd I a | 8.90K | 0.15% | 0.00% | Sep 2024 |
Top institutions holding NCNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| StoneX Group Inc | 47.0K | 1.13% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 27.1K | 0.65% | +95.59% | Jun 2026 |
| HRT FINANCIAL LLC | 16.9K | 0.41% | 0.00% | Jun 2026 |
| Glass Jacobson Investment Advisors LLC | 15.0K | 0.36% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 4.70K | 0.11% | 0.00% | Sep 2026 |
| Integrated Wealth Concepts LLC | 188.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 188.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 5.00 | 0.00% | +150.00% | Jun 2026 |
| Acadian Asset Management LLC | 2.00 | 0.00% | 0.00% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
NuCana PLC company profile
- Company name
- NuCana PLC
- Ticker
- NCNA.US
- Exchange
- USA Stocks
- Listed since
- Sep 28, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT
- Phone
- 44 13 1357 1111
- Website
- nucana.com
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
NuCana PLC management
8- Mr. Hugh Stephen GriffithFounder, CEO & Executive Director · born 1968
- Mr. Ian WebsterChief Financial Officer · born 1981
- Prof. David HarrisonHead of Translational Medicine & Studies · born 1960
- Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical Officer · born 1958
- Ms. Theresa BruceChief Operating Officer · born 1965
- Mr. Gordon KennovinSenior VP of CMC & Development
- Dr. Stuart GrantSenior Vice President of Regulatory Affairs
- Mr. Martin Alexander QuinnCompany Secretary